A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo

► GLP-1 analog (GLP715a) containing an inter-disulfide bond and a Trp-cage extended its half-life. ► The analog (GLP715a) remained the biological activity of GLP-1. ► GLP715a showed better glucose tolerance and higher HbA1c reduction than GLP-1. ► GLP715a might be utilized as a long-lasting drug for type 2 diabetes.